Pilot Study of Oral Valganciclovir Therapy in Patients With Classic Kaposi Sarcoma

We conducted a clinical trial of oral valganciclovir, a drug with in vitro activity against Kaposi sarcoma (KS) — associated herpesvirus (KSHV), in classic KS. Five human immunodeficiency virus-seronegative participants received valganciclovir for up to six 4-week cycles at doses used for cytomegalo...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2011-04, Vol.203 (8), p.1082-1086
Main Authors: Krown, Susan E., Dittmer, Dirk P., Cesarman, Ethel
Format: Article
Language:English
Subjects:
Administration, Oral
Adult
Aged
AIDS
Antigens
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Biopsies
Dosage
Endothelial cells
Fundamental and applied biological sciences. Psychology
Ganciclovir - administration & dosage
Ganciclovir - adverse effects
Ganciclovir - analogs & derivatives
Ganciclovir - therapeutic use
Herpesviridae
Herpesvirus 8, Human
Human herpesvirus 8
Humans
Infectious diseases
Kaposi sarcoma
Lesions
Major and Brief Reports
Medical sciences
Messenger RNA
Microbiology
Middle Aged
Sarcoma, Kaposi - drug therapy
Tumors
Valganciclovir
VIRUSES
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We conducted a clinical trial of oral valganciclovir, a drug with in vitro activity against Kaposi sarcoma (KS) — associated herpesvirus (KSHV), in classic KS. Five human immunodeficiency virus-seronegative participants received valganciclovir for up to six 4-week cycles at doses used for cytomegalovirus infection. None of the study subjects showed an objective response; KS progressed in 4 subjects after 1-4 cycles and remained stable in 1 subject after 6 cycles. KS biopsies showed minimal lytic KSHV antigen and gene expression at baseline and no treatment-associated changes. Although valganciclovir was not active against KS in this setting, other appropriately targeted anti-herpesviral strategies may prove to be more effective.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/jiq177